These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 32664222)

  • 1. FimH and Anti-Adhesive Therapeutics: A Disarming Strategy Against Uropathogens.
    Sarshar M; Behzadi P; Ambrosi C; Zagaglia C; Palamara AT; Scribano D
    Antibiotics (Basel); 2020 Jul; 9(7):. PubMed ID: 32664222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin.
    Bouckaert J; Berglund J; Schembri M; De Genst E; Cools L; Wuhrer M; Hung CS; Pinkner J; Slättegård R; Zavialov A; Choudhury D; Langermann S; Hultgren SJ; Wyns L; Klemm P; Oscarson S; Knight SD; De Greve H
    Mol Microbiol; 2005 Jan; 55(2):441-55. PubMed ID: 15659162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insightful Improvement in the Design of Potent Uropathogenic
    Mousavifar L; Sarshar M; Bridot C; Scribano D; Ambrosi C; Palamara AT; Vergoten G; Roubinet B; Landemarre L; Bouckaert J; Roy R
    Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rational design strategies for FimH antagonists: new drugs on the horizon for urinary tract infection and Crohn's disease.
    Mydock-McGrane LK; Hannan TJ; Janetka JW
    Expert Opin Drug Discov; 2017 Jul; 12(7):711-731. PubMed ID: 28506090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transurethral instillation with fusion protein MrpH.FimH induces protective innate immune responses against uropathogenic Escherichia coli and Proteus mirabilis.
    Habibi M; Asadi Karam MR; Bouzari S
    APMIS; 2016 Jun; 124(6):444-52. PubMed ID: 26918627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bacterial Lectin FimH and Its Aggregation Hot-Spots: An Alternative Strategy against Uropathogenic
    Nasi GI; Georgakopoulou KI; Theodoropoulou MK; Papandreou NC; Chrysina ED; Tsiolaki PL; Iconomidou VA
    Pharmaceutics; 2023 Mar; 15(3):. PubMed ID: 36986878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. d-Mannose Treatment neither Affects Uropathogenic
    Scribano D; Sarshar M; Prezioso C; Lucarelli M; Angeloni A; Zagaglia C; Palamara AT; Ambrosi C
    Molecules; 2020 Jan; 25(2):. PubMed ID: 31941080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Target Selectivity of FimH Antagonists.
    Scharenberg M; Schwardt O; Rabbani S; Ernst B
    J Med Chem; 2012 Nov; 55(22):9810-6. PubMed ID: 23088608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective depletion of uropathogenic E. coli from the gut by a FimH antagonist.
    Spaulding CN; Klein RD; Ruer S; Kau AL; Schreiber HL; Cusumano ZT; Dodson KW; Pinkner JS; Fremont DH; Janetka JW; Remaut H; Gordon JI; Hultgren SJ
    Nature; 2017 Jun; 546(7659):528-532. PubMed ID: 28614296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.
    Mydock-McGrane LK; Cusumano ZT; Janetka JW
    Expert Opin Ther Pat; 2016; 26(2):175-97. PubMed ID: 26651364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The affinity of the FimH fimbrial adhesin is receptor-driven and quasi-independent of Escherichia coli pathotypes.
    Bouckaert J; Mackenzie J; de Paz JL; Chipwaza B; Choudhury D; Zavialov A; Mannerstedt K; Anderson J; Piérard D; Wyns L; Seeberger PH; Oscarson S; De Greve H; Knight SD
    Mol Microbiol; 2006 Sep; 61(6):1556-68. PubMed ID: 16930149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human Urine Decreases Function and Expression of Type 1 Pili in Uropathogenic Escherichia coli.
    Greene SE; Hibbing ME; Janetka J; Chen SL; Hultgren SJ
    mBio; 2015 Jun; 6(4):e00820. PubMed ID: 26126855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antivirulence Isoquinolone Mannosides: Optimization of the Biaryl Aglycone for FimH Lectin Binding Affinity and Efficacy in the Treatment of Chronic UTI.
    Jarvis C; Han Z; Kalas V; Klein R; Pinkner JS; Ford B; Binkley J; Cusumano CK; Cusumano Z; Mydock-McGrane L; Hultgren SJ; Janetka JW
    ChemMedChem; 2016 Feb; 11(4):367-73. PubMed ID: 26812660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dimeric and Trimeric Fusion Proteins Generated with Fimbrial Adhesins of Uropathogenic
    Luna-Pineda VM; Reyes-Grajeda JP; Cruz-Córdova A; Saldaña-Ahuactzi Z; Ochoa SA; Maldonado-Bernal C; Cázares-Domínguez V; Moreno-Fierros L; Arellano-Galindo J; Hernández-Castro R; Xicohtencatl-Cortes J
    Front Cell Infect Microbiol; 2016; 6():135. PubMed ID: 27843814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the effect of MPL and delivery route on immunogenicity and protectivity of different formulations of FimH and MrpH from uropathogenic Escherichia coli and Proteus mirabilis in a UTI mouse model.
    Habibi M; Asadi Karam MR; Bouzari S
    Int Immunopharmacol; 2015 Sep; 28(1):70-8. PubMed ID: 26033493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal immunization with fusion protein MrpH·FimH and MPL adjuvant confers protection against urinary tract infections caused by uropathogenic Escherichia coli and Proteus mirabilis.
    Habibi M; Asadi Karam MR; Shokrgozar MA; Oloomi M; Jafari A; Bouzari S
    Mol Immunol; 2015 Apr; 64(2):285-94. PubMed ID: 25562574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Conformational Variability of FimH: Which Conformation Represents the Therapeutic Target?
    Eris D; Preston RC; Scharenberg M; Hulliger F; Abgottspon D; Pang L; Jiang X; Schwardt O; Ernst B
    Chembiochem; 2016 Jun; 17(11):1012-20. PubMed ID: 26991759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetic properties of carbohydrate-lectin interactions: FimH antagonists.
    Scharenberg M; Jiang X; Pang L; Navarra G; Rabbani S; Binder F; Schwardt O; Ernst B
    ChemMedChem; 2014 Jan; 9(1):78-83. PubMed ID: 24357503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developments in Mannose-Based Treatments for Uropathogenic Escherichia coli-Induced Urinary Tract Infections.
    Hatton NE; Baumann CG; Fascione MA
    Chembiochem; 2021 Feb; 22(4):613-629. PubMed ID: 32876368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Binding of the Bacterial Adhesin FimH to Its Natural, Multivalent High-Mannose Type Glycan Targets.
    Sauer MM; Jakob RP; Luber T; Canonica F; Navarra G; Ernst B; Unverzagt C; Maier T; Glockshuber R
    J Am Chem Soc; 2019 Jan; 141(2):936-944. PubMed ID: 30543411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.